Angela Shen

General Surgery
163 Amsterdam Ave
New York, NY 10023

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Journal: Investigational new drugs
Published: May 24, 2016
Showing 1-1 of 1

Last Updated: 09/26/2026